Red Crane Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Red Crane Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$484K	Sell	506,460 -90,803	-15%	-$100K	0.34%	57
2026 Q2	$782K	Hold	597,263	–	–	0.58%	42
2026 Q1	$944K	Hold	597,263	–	–	0.78%	34
2025 Q4	$997K	Buy	597,263 +85,900	+17%	+$149K	0.82%	34
2025 Q3	$864K	Buy	511,363 +15,365	+3%	+$18.2K	0.73%	34
2025 Q2	$450K	Buy	495,998 +2	+0%	+$1	0.41%	43
2025 Q1	$224K	Buy	495,996 +155,760	+46%	+$91.4K	0.21%	61
2024 Q4	$171K	Buy	+340,236	New	+$250K	0.16%	64

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return

Red Crane Wealth Management's LCTX Position: Q3 2026 in Review

Red Crane Wealth Management reduced its Lineage Cell Therapeutics (LCTX) stake by 15% in Q3 2026, selling an estimated $100K and leaving 506,460 shares worth $484K. The position accounts for 0.34% of the portfolio, ranked #57.

Red Crane Wealth Management first reported a position in LCTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $997K in Q4 2025. 57 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Red Crane Wealth Management held 506,460 shares of Lineage Cell Therapeutics worth $484K as of Q3 2026.
Red Crane Wealth Management sold 90,803 Lineage Cell Therapeutics shares in Q3 2026, an estimated $100K.
Lineage Cell Therapeutics made up 0.34% of Red Crane Wealth Management's portfolio in Q3 2026, its #57 holding.
Red Crane Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 8 quarters since.
Red Crane Wealth Management's Lineage Cell Therapeutics position peaked at $997K in Q4 2025.
57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Red Crane Wealth Management's 13F filing for Q3 2026, filed 14 Oct 2026.